Breaking Finance News

Roth Capital announced Syros Pharmaceuticals (NDAQ:SYRS), boosting its stock price target to $15.00 today

In a report released on 10/23/2017 Roth Capital increased the stock price target of Syros Pharmaceuticals (NDAQ:SYRS) to $15.00 reporting a possible downside of -0.12%.

Just yesterday Syros Pharmaceuticals (NDAQ:SYRS) traded 0.48% higher at $17.00. Syros Pharmaceuticals’s 50-day moving average is $16.06 and its 200-day moving average is $16.06. The last stock price is up 3.28% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 28,826 shares of SYRS traded hands, down from an average trading volume of 197,580

Recent Performance Chart

Syros Pharmaceuticals (NDAQ:SYRS)

Syros Pharmaceuticals has with a one year low of $10.22 and a one year high of $24.38 and has a market capitalization of $0.

General Company Details For Syros Pharmaceuticals (NDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *